Interferon gamma‐1b for the treatment of fibrosis in chronic hepatitis C infection
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Summary. Given that the complications of hepatitis C are due to fibrosis, we hypothesized that the antifibrotic effects of interferon gamma on stellate cells would lead to beneficial effects in patients with hepatitis C. Thus, we evaluated the safety and efficacy of interferon gamma‐1b in patients with hepatitis C. A cohort of 20 patients with chronic hepatitis C who failed or were intolerant to previous interferon‐alpha‐based regimens received 200 μ g of interferon gamma‐1b subcutaneously three times weekly for 24 weeks. Liver biopsy was performed prior to and at the end of treatment. Biopsies were evaluated by a single blinded pathologist using the Knodell system modified by Ishak, and fibrosis was also quantitated by morphometric analysis. The study population was 75% male and 70% Caucasian. Mean age was 47.9 ± 7.5 years. Eighteen of 20 patients completed therapy. One patient discontinued therapy because of constitutional symptoms. One patient discontinued therapy because of elevated aminotransferases greater than twice baseline. No serious adverse events occurred. Morphometric analysis revealed that six patients (30%) had >1% absolute reduction in fibrosis score. Four of 20 (20%) patients had improvement in Ishak fibrosis scores after treatment. In conclusion, interferon gamma therapy is safe and well tolerated in patients with chronic hepatitis C. Although we did not detect an overall reduction in fibrosis, interferon gamma‐1b treatment led to a reduction in fibrosis in selected patients. These data provide a basis for further study of interferon gamma‐1b in patients with chronic fibrosing liver disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial
Lindor, K. D., Kowdley, K. V., Heathcote, J. E., Harrison, E. M., Jorgensen, R., Angulo, P., Lymp, J. F., Burgart, L., & Colin, P. (2004) · Hepatology · doi:10.1002/hep.20092 · Cited by 727
Shi, Z., Wakil, A. E., & Rockey, D. C. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.20.10663 · Cited by 310
Self-citationInhibition of Rat Hepatic Lipocyte Activation in Culture by Interferon–γ
Rockey, D. C., Maher, J. J., Jarnagin, W. R., Gabbiani, G., & Friedman, S. L. (1992) · Hepatology · doi:10.1002/hep.1840160325 · Cited by 179
Self-citation
Cited by
Fibrosis–a common pathway to organ injury and failure
Rockey, D. C., Bell, P. D., & Hill, J. A. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1300575 · Cited by 1,428
Self-citationHepatic inflammation and fibrosis: Functional links and key pathways
Seki, E., & Schwabe, R. F. (2015) · Hepatology · doi:10.1002/hep.27332 · Cited by 972
The Global Impact of Hepatic Fibrosis and End-Stage Liver Disease
Lim, Y.-S., & Kim, W. R. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2008.07.007 · Cited by 316
Miller, C. H. T., Maher, S. G., & Young, H. A. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05069.x · Cited by 303
Jeong, W.-I., Park, O., Radaeva, S., & Gao, B. (2006) · Hepatology · doi:10.1002/hep.21419 · Cited by 275
Metadata
- Authors
- Muir, A. J., Sylvestre, P. B., & Rockey, D. C.
- Venue
- Journal of Viral Hepatitis
- Publisher
- Wiley
- Published
- 2006-01-24
- Volume
- 13
- Issue
- 5
- Pages
- 322-328
- ISSN
- 1352-0504 (ISSN-L)
- 1365-2893
- OpenAlex
- W2082473800
- Cited by
- 62
- References
- 4
- FWCI
- 4.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Interferon gamma‐1b for the treatment of fibrosis in chronic hepatitis C infection. https://app.cochat.ai/papers/10.1111/j.1365-2893.2005.00689.x
- The paper
- Muir, A. J., Sylvestre, P. B., & Rockey, D. C. (2006). Interferon gamma‐1b for the treatment of fibrosis in chronic hepatitis C infection. Journal of Viral Hepatitis. https://doi.org/10.1111/j.1365-2893.2005.00689.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.